MRI measures of disease activity in active UC
Research type
Research Study
Full title
MagnetiC ResOnance ImagiNg of intrabdominal lymphatiCs and vasculaturE as measures of disease activity in Ozanimod-treated patients with active UlceratIVE Colitis (CONCEIVE)
IRAS ID
334239
Contact name
Gordon William Moran
Contact email
Sponsor organisation
University of Nottingham
Duration of Study in the UK
4 years, 2 months, 1 days
Research summary
Magnetic resonance imaging (MRI) is a powerful technique for diagnosing disease and investigating how the body works. The Sir Peter Mansfield Imaging Centre at the University of Nottingham has pioneered the development of MRI and continues to be at the forefront of work in this area. An exciting feature is its ability to produce information about what is happening inside the body (e.g., changes in blood flow and lymph nodes)
Using MRI techniques we’ve previously been able to measure changes in lymph node size. Using the same technique, we’ve shown a significant difference in lymph node size in patients with active Crohn’s disease when compared to healthy volunteers. These observations suggest that lymph node size and activity may provide possible biomarkers to measure disease activity in inflammatory bowel disease.
In this study, we will use MRI to track the changes that occur in lymph nodes and abdominal blood vessels in patients with Ulcerative Colitis (UC) treated with ozanimod therapy and investigate if baseline MRI measures can predict clinical response.
We will recruit adult NHS patients with active UC, due to commence Ozanimod therapy and use MRI scan measures at baseline, 3, 6 & 12 months of Ozanimod treatment to investigate if baseline measures can predict clinical response. Participants will undergo 4 MRI scans over 52 weeks. The preliminary data obtained will be used to inform a future larger study to build on this work.REC name
North West - Preston Research Ethics Committee
REC reference
24/NW/0021
Date of REC Opinion
19 Jan 2024
REC opinion
Favourable Opinion